
Why ALA Supports Keeping the Name Lipedema
You may have heard recent discussions about changing the name Lipedema to Lipalgia Syndrome. But what does that mean, and why does it matter?
In September 2026, the International Lipoedema Association (ILA) announced its support for the name Lipalgia Syndrome, which places a greater emphasis on pain as a defining symptom of the condition.
The American Lipedema Association (ALA) does not support changing the name at this time.
Lipedema is a complex condition that involves more than pain alone. While research continues to improve our understanding of the disease, there are still important questions about its underlying causes.
The name lipedema is also becoming more widely recognized by healthcare professionals, researchers, and insurers. Changing it now could create confusion and complicate ongoing efforts to improve diagnosis, education, and access to care.
ALA believes any future name change should be guided by stronger scientific understanding and international agreement that includes patients, healthcare professionals, and researchers.
We believe the priority should be advancing research, improving awareness, and helping people living with lipedema get the care they deserve.
Read ALA’s Full Position Paper (PDF) below to learn more about why we support keeping the name lipedema.
FAQ’s about renaming Lipedema
General FAQs
What is being proposed?
The ILA has endorsed replacing the name lipedema with lipalgia syndrome. Some clinics and training organizations have adopted the new term. No international health body has changed the name or the diagnosis codes.
Who is the ILA?
The International Lipoedema Association is an organization based in Denmark that works with healthcare professionals on lipoedema care and research. Its board endorsed the new name in September 2026.
Why does the ALA disagree?
The proposed names describe one or two features of a complex disease. Lipalgia describes pain, which occurs in many conditions. The science on what causes lipedema is still developing, so renaming now would be premature.
Does the ALA think lipedema is the same as lymphedema?
No. Lipedema and lymphedema are distinct conditions. Our point is narrower: current evidence does not rule out a tissue-fluid component in lipedema, and that question deserves more research.
Could the name ever change?
Yes. If research identifies the causes or distinct types of the disease, a more precise name could make sense. That decision should come from an international consensus of clinicians, researchers, and patient organizations.
Patients and Members FAQs
Does this change my diagnosis?
No. Your condition is the same whatever it is called. In the United States, lipedema remains the name used by the ALA and in the new diagnosis codes. The ILA has also stated that diagnosis, coding, and access to treatment are unchanged.
My therapist or doctor called it lipalgia syndrome. Are they wrong?
They are describing the same condition. Some clinicians trained abroad or through certain programs now use the new term. You can mention both names, and it helps to keep “lipedema” in your medical records and insurance paperwork.
Will this affect my insurance coverage?
The name change itself does not alter any coverage policy. Insurers write policies around diagnosis codes, and those use the name lipedema. Consistent terminology helps patients get comprehensive care covered, including MLD, compression, and lipedema reduction surgery.
Should I change my treatment?
No. Nothing about this debate changes your current care. Talk with your healthcare provider before starting or stopping any treatment.
How can I help?
Keep using the name lipedema when you talk with providers, insurers, and others. Share the ALA position paper. When the new US codes arrive in October 2027, ask your providers whether they are using them.
Clinicians and Therapists FAQs
What term should I use in documentation?
Use “lipedema,” which matches the ICD-11 code and the new US ICD-10-CM codes. To describe pain, “lipalgia secondary to lipedema” keeps the disease and the symptom distinct.
Some CLT training programs now teach the new name. Should I use it?
Klose Training, one US organization that trains clinicians for the Certified Lymphedema Therapist (CLT) credential, has adopted the new term. Other US CLT training organizations have not. We encourage clinicians to use “lipedema” so patient records, codes, and insurance claims stay consistent.
What is the evidence for a fluid component?
Crescenzi et al. (2018, 2020) and Nöll et al. (2026) measured higher sodium in the skin and fat of women with lipedema than in controls. Skin sodium rose with disease stage and predicted pain. One MLD session lowered fat sodium and pain, while fat fraction did not change. Atan and Bahar-Özdemir (2021) found that complete decongestive therapy improved limb volume, pain, and function.
What are the limits of that evidence?
The Nöll study included 15 women with lipedema, measured one slice of the calf, and tested a single session. Higher sodium does not by itself prove excess water. These are reasons to fund larger studies, not to dismiss the findings.
What does the LIPLEG trial tell us?
LIPLEG randomized 410 women at 11 German centers. At 12 months, 68% of the liposuction group had meaningful pain reduction, compared with 8% with conservative care. Surgery also improved physical function, which may have contributed to pain relief. The trial confirms the central role of diseased fat tissue without settling what drives pain.
Media FAQs
Is this a dispute between patient groups?
It is a scientific discussion about how best to name a complex disease. We share the ILA’s goal of naming lipedema accurately. We differ on the evidence and the timing, and we welcome working together on the research.
Does the ALA stand alone in this view?
No. The Lipedema World Alliance, whose members include most lipedema patient organizations worldwide along with researchers and clinicians, has not recommended changing the disease name or the diagnosis codes.
Why does a name matter so much?
A name shapes how clinicians learn about a disease, how insurers write coverage policies, and how patients find answers. In the United States, lipedema is still poorly recognized. Two competing names would slow the progress patients are waiting for.
What would the ALA like to see happen?
We would like research into the causes of lipedema to continue, followed by an international consensus process on terminology. Patient organizations should have a seat at that table.
Insurers and Partners FAQs
Should coverage policies change their terminology?
No. Lipedema remains the name in ICD-11 (EF02.2), in national codes such as Germany’s, and in the new US ICD-10-CM codes effective October 1, 2027. Policies that use “lipedema” stay aligned with those codes.
Does the debate change the evidence for treatment?
No. The debate concerns the name, not the treatments. The LIPLEG trial supports lipedema reduction surgery for appropriate patients, and studies of MLD and decongestive therapy support conservative care.
How should partners refer to the condition?
We recommend “lipedema” in US materials, with “lipoedema” as the accepted European spelling. If a partner needs to reference the proposal, a neutral phrasing works well: “lipedema, which some organizations have proposed renaming lipalgia syndrome.”
